



Cancer Incidence Rates, 2017-2021 per 100,000 population by site and gender

Vermont Cancer Registry

July 2024

Male and Female					Male					Female				
Cancer Site	U.S. Rate (All Races)	N.E. Rate (All Races)	VT Rate (All Races)	VT Cases (per year)	Cancer Site	U.S. Rate (All Races)	N.E. Rate (All Races)	VT Rate (All Races)	VT Cases (per year)	Cancer Site	U.S. Rate (All Races)	N.E. Rate (All Races)	VT Rate (All Races)	VT Cases (per year)
All Sites	444.6	461.3	454.7 ▲	4,033	All Sites	481.3	498.4	485.9 ▼	2,091	All Sites	421.3	439.3	433.9 ▲	1,942
Lung and Bronchus	53.3	54.8	54.8	519	Prostate	113.1	123.6	108.7 ▼	523	Breast	129.8	134.7	129.2	563
Melanoma of the Skin	22.7	19.4	35.7 ▲ ▲	300	Lung and Bronchus	59.6	59.6	60.1	268	Lung and Bronchus	48.5	51.7	50.6	251
Colon and Rectum	36.4	35.6	33.2 ▼ ▼	281	Melanoma of the Skin	28.7	24.4	40.6 ▲ ▲	165	Uterus	27.8	30.8	31.2 ▲	155
Urinary Bladder	18.8	21.5	22.6 ▲	211	Colon and Rectum	41.4	40.4	39.3	156	Melanoma of the Skin	18.4	16.0	32.2 ▲ ▲	134
Non-Hodgkin Lymphoma	18.5	19.9	19.0	170	Urinary Bladder	32.5	37.1	38.0 ▲	160	Colon and Rectum	32.1	31.5	27.6 ▼ ▼	125
Kidney	17.3	16.1	15.6 ▼	137	Non-Hodgkin Lymphoma	22.3	23.9	22.4	93	Thyroid	19.0	23.9	19.9 ▼	66
Thyroid	12.9	16.4	13.1 ▼	90	Kidney	23.4	22.3	20.2 ▼	86	Non-Hodgkin Lymphoma	15.4	16.8	16.1	77
Leukemia	14.1	14.7	13.7	115	Oral Cavity/Throat	18.0	17.2	20.1 ▲	87	Pancreas	11.9	12.7	12.2	59
Pancreas	13.5	14.3	12.9 ▼	118	Leukemia	17.8	18.9	16.6	67	Kidney	12.0	10.8	11.5 ▼	51
Oral Cavity/Throat	12.0	11.6	13.0 ▲	116	Pancreas	15.3	16.3	13.8 ▼	59	Urinary Bladder	8.1	9.8	10.1 ▲	51
Brain/Nervous System	6.3	6.6	7.7 ▲ ▲	59	Esophagus	7.8	8.0	9.3 ▲	41	Leukemia	11.0	11.5	11.2	48
Myeloma	7.1	7.3	6.5	58	Brain/Nervous System	7.4	7.8	8.9	34	Ovary	10.1	10.5	9.5	41
Liver	8.6	8.1	6.2 ▼ ▼	60	Liver	12.8	12.3	8.9 ▼ ▼	43	Oral Cavity/Throat	6.6	6.7	6.5	29
Stomach	6.3	7.1	5.9 ▼	51	Testis	5.7	6.0	7.9 ▲ ▲	23	Brain/Nervous System	5.3	5.6	6.7	25
Esophagus	4.5	4.7	5.3	50	Stomach	8.3	9.5	8.0	34	Cervix	7.5	6.6	5.7	20
Larynx	2.9	2.8	3.0	28	Myeloma	8.6	9.0	8.2	33	Myeloma	5.8	6.0	5.2	25
Hodgkin Lymphoma	2.5	2.9	2.8	19	Thyroid	6.9	8.8	6.4 ▼	24	Stomach	4.7	5.2	4.0 ▼	17
					Larynx	4.9	4.8	4.9	22	Liver	4.9	4.5	3.7 ▼	17
					Hodgkin Lymphoma	2.8	3.3	3.5	12	Hodgkin Lymphoma	2.3	2.6	2.2	8
										Esophagus	1.8	1.9	1.7	9
										Larynx	1.1	1.1	1.4	6

▲ Statistically higher than the U.S. rate. ▲ Statistically higher than the N.E. rate.
▼ Statistically lower than the U.S. rate. ▼ Statistically lower than the N.E. rate.

TECHNICAL NOTES: Rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population (19 age groups – Census P25–1130) and exclude basal cell and squamous cell skin cancers. Incidence rates exclude in situ carcinomas except urinary bladder. Incidence data were coded using the International Classification of Disease for Oncology (ICD-O) coding system. Vermont cases include Vermont residents only. The Vermont and U.S. incidence rates are based on the Vermont Cancer Registry, Vermont Department of Health (1994-2022) and the NPCR and SEER Incidence - U.S. Cancer Statistics Public Use Database, 2023 submission (2001-2021), United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Released June 2024. Available at www.cdc.gov/cancer/uscs/public-use. Northeast Region (N.E.) includes Connecticut, Maine, Massachusetts, New Hampshire, New York, Pennsylvania, Rhode Island, and Vermont. A reporting delay by Department of Veterans Affairs (VA) has resulted in incomplete reporting of VA hospital cases in 2011-2014, 2017-2021.

COPYRIGHT INFORMATION: All material in this report is in the public domain and may be reproduced or copied without permission. Citation as to source is appreciated. This document can be made available in other accessible formats.

SUGGESTED CITATION: Age Adjusted Cancer Incidence Rates, 2017-2021, Vermont Department of Health, Burlington, VT, 2024.

ACKNOWLEDGEMENT: This publication was supported by the Grant or Cooperative Agreement NU58DP007149, funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services.



Cancer Mortality Rates, 2017-2021 per 100,000 population by site and gender

Vermont Cancer Registry

July 2024

Male and Female					Male					Female				
Cancer Site	U.S. Rate (All Races)	N.E. Rate (All Races)	VT Rate (All Races)	VT Deaths (per year)	Cancer Site	U.S. Rate (All Races)	N.E. Rate (All Races)	VT Rate (All Races)	VT Deaths (per year)	Cancer Site	U.S. Rate (All Races)	N.E. Rate (All Races)	VT Rate (All Races)	VT Deaths (per year)
All Sites	148.4	141.7	154.8 ▲ ▲	1,409	All Sites	176.5	168.4	184.8 ▲ ▲	760	All Sites	128.3	123.6	132.2 ▲	649
Lung and Bronchus	33.8	31.8	34.0 ▲	318	Lung and Bronchus	40.6	37.5	39.1	169	Lung and Bronchus	28.6	27.7	29.9	150
Colon and Rectum	13.1	11.9	13.3 ▲	117	Prostate	19.2	17.8	21.9 ▲ ▲	83	Breast	19.6	17.9	17.1 ▼	83
Pancreas	11.2	11.3	11.6	109	Colon and Rectum	15.6	14.1	15.6	62	Colon and Rectum	10.9	10.1	11.3	54
Leukemia	6.0	5.7	5.6	50	Pancreas	12.9	13.1	12.6	54	Pancreas	9.8	9.9	10.7	54
Non-Hodgkin Lymphoma	5.1	5.0	5.2	46	Esophagus	6.6	6.8	9.6 ▲ ▲	42	Uterus	5.2	5.6	6.8 ▲ ▲	34
Brain/Nervous System	4.4	4.3	5.7 ▲ ▲	49	Liver	9.6	8.7	8.5	39	Ovary	6.2	6.2	6.1	29
Liver	6.6	5.9	6.0	57	Urinary Bladder	7.2	7.3	7.8	30	Leukemia	4.5	4.2	4.4	21
Esophagus	3.8	3.8	5.2 ▲ ▲	49	Non-Hodgkin Lymphoma	6.7	6.6	7.3	28	Brain/Nervous System	3.6	3.4	4.8 ▲ ▲	22
Urinary Bladder	4.2	4.1	4.4	40	Leukemia	8.0	7.8	7.3	29	Non-Hodgkin Lymphoma	3.8	3.8	3.6	18
Kidney	3.5	2.9	3.3	31	Brain/Nervous System	5.4	5.3	6.7 ▲ ▲	27	Liver	4.2	3.6	3.8	18
Myeloma	3.1	2.8	2.8	26	Kidney	5.1	4.3	5.3	22	Urinary Bladder	2.0	2.0	2.0	10
Oral Cavity/Throat	2.6	2.3	2.7	25	Oral Cavity/Throat	4.0	3.5	4.1	18	Myeloma	2.4	2.2	2.1	11
Melanoma of the Skin	2.1	1.9	2.1	18	Myeloma	3.9	3.6	3.7	16	Kidney	2.2	1.8	1.8	8
Stomach	2.8	2.8	2.2	19	Stomach	3.7	3.8	3.2	13	Esophagus	1.4	1.4	1.4	7
Larynx	0.9	0.8	0.8	8	Melanoma of the Skin	3.0	2.8	2.9	11	Melanoma of the Skin	1.3	1.3	1.5	7
Thyroid	0.5	0.5	0.4	4	Larynx	1.6	1.5	1.4	6	Cervix	2.2	1.7	1.7	6
Hodgkin Lymphoma	0.3	0.2	0.2	2	Thyroid	0.5	0.5	0.5	2	Oral Cavity/Throat	1.4	1.3	1.4	7
					Testis	0.3	0.2	--	<1	Stomach	2.1	2.0	1.4	6
					Hodgkin Lymphoma	0.3	0.3	--	<1	Thyroid	0.5	0.5	0.4	2
										Larynx	0.3	0.3	0.3	1
										Hodgkin Lymphoma	0.2	0.2	--	1

▲ Statistically higher than the U.S. rate. ▲ Statistically higher than the N.E. rate.
▼ Statistically lower than the U.S. rate. ▼ Statistically lower than the N.E. rate.

TECHNICAL NOTES: Rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population (19 age groups – Census P25–1130) and exclude basal cell and squamous cell skin cancers. Mortality data were coded using the International Classification of Disease Tenth Revision (ICD-10) coding system. Vermont deaths include Vermont residents only. -- Rates based on 5 or fewer deaths are not individually calculated. The Vermont and the U.S. mortality rates are based on the Vermont Vital Statistics System, Vermont Department of Health (1994-2021) and the Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Mortality - All COD, Aggregated With State, Total U.S. (1990-2021) <Katrina/Rita Population Adjustment>, National Cancer Institute, DCCPS, Surveillance Research Program, released June 2024. Underlying mortality data provided by NCHS (www.cdc.gov/nchs). Northeast Region (N.E.) includes Connecticut, Maine, Massachusetts, New Hampshire, New York, Pennsylvania, Rhode Island, and Vermont.

COPYRIGHT INFORMATION: All material in this report is in the public domain and may be reproduced or copied without permission. Citation as to source is appreciated. This document can be made available in other accessible formats.

SUGGESTED CITATION: Age Adjusted Cancer Mortality Rates, 2017-2021, Vermont Department of Health, Burlington, VT, 2024.

ACKNOWLEDGEMENT: This publication was supported by the Grant or Cooperative Agreement NU58DP007149, funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services.